Attovia's ATTO-1310 shows durable itch relief in Phase 1b topline results

What's the deal? Attovia reported positive 12-week topline results on 5 November 2026 from its Phase 1b study of ATTO-1310, an experimental antibody-based therapy that blocks IL-31, a protein that drives itching, in patients with chronic pruritus (persistent itch with no identifiable cause) and high-itch atopic dermatitis (eczema). A single subcutaneous dose of 4.5 or 9 mg/kg was tested against placebo in patients across 17 sites in the US and Canada.

Why it matters: One dose produced rapid, deep and durable itch relief. Among chronic-itch patients, 82% achieved at least a four-point reduction on the 0–10 Peak Pruritus Numerical Rating Scale at week 12 versus 22% on placebo, and 47% were itch-free or nearly itch-free versus 0% on placebo. In eczema patients, 44% achieved the four-point itch response and 44% had at least 75% improvement in skin lesions at week 12, compared with 13% on placebo. IL-31 was suppressed by roughly 95% through week 12, which Attovia says supports potential quarterly dosing. The drug was generally well tolerated, with no study discontinuations among patients; one unrelated serious adverse event was reported. Attovia plans two Phase 2 trials — ATTUNE-CPUO (about 300 people) and ATTUNE-AD (about 255 people) — starting in the first half of 2027. Chronic itching is estimated to affect two to five million US adults, a group with no FDA-approved treatment.

Read more: Attovia Therapeutics, 5 November 2026 · GlobeNewswire, 5 November 2026